TD SYNNEX Free cash flow decreased by 165.3% to -$929.01M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.7%, from -$789.52M to -$929.01M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $274.48M | $0.00 | $520.22M | -$1.35B | -$99.33M | -$140.07M | $677.21M | $552.15M | $168.08M | $343.62M | $338.64M | $512.88M | -$789.52M | $1.42B | -$929.01M |
| QoQ Change | — | -100.0% | — | -358.7% | +92.6% | -41.0% | +583.5% | -18.5% | -69.6% | +104.4% | -1.4% | +51.5% | -253.9% | +280.1% | -165.3% |
| YoY Change | — | — | — | — | — | +89.6% | — | +655.9% | — | +345.3% | -38.7% | +205.1% | -329.8% | +177.3% | -17.7% |